Related Experiment Videos
Treatment of hepatitis B
1Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362, USA.
Journal of Gastroenterology
|November 9, 2002
Summary
This review examines current treatments for chronic hepatitis B virus (HBV) infection, including interferon alpha and lamivudine. It updates safety and efficacy data and discusses management strategies for different patient groups.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection impacts 350 million globally.
- Treatment aims to suppress HBV replication and achieve liver disease remission.
- Current antiviral therapy is restricted to specific patient phases (immune clearance or active liver disease).
Purpose of the Study:
- To review the safety and efficacy of interferon alpha and lamivudine for chronic hepatitis B.
- To discuss management strategies in various clinical scenarios.
- To explore future treatment options for chronic hepatitis B.
Main Methods:
- Literature review of safety and efficacy data.
- Analysis of current treatment guidelines and clinical scenarios.
- Discussion of emerging therapeutic approaches.
Main Results:
- Interferon alpha and lamivudine efficacy and safety data were updated.
- Management strategies for immune clearance, active disease, immune tolerance, and inactive carrier states were analyzed.
- Limitations of current treatments in specific phases were highlighted.
Conclusions:
- Current treatments have limitations in certain phases of chronic hepatitis B.
- Interferon alpha and lamivudine remain important therapeutic options.
- Further research into novel treatments is crucial for improving patient outcomes.